BACKGROUND: Systemic-pulmonary collateral (SPC) flow occurs commonly in single ventricle patients after superior cavo-pulmonary connection, with unclear clinical significance. We sought to evaluate the association between SPC flow and acute post-Fontan clinical outcomes using a novel method of quantifying SPC flow by cardiac magnetic resonance (CMR) imaging. METHODS AND RESULTS: All patients who had SPC flow quantified by CMR imaging before Fontan were retrospectively reviewed to assess for acute clinical outcomes after Fontan completion. Forty-four subjects were included who had Fontan completion between May 2008 and September 2010. SPC flow prior to Fontan measured 1.5±0.9 L/min/m(2), accounting for 31±11% of total aortic flow and 44±15% of total pulmonary venous flow. There was a significant linear association between natural log-transformed duration of hospitalization and SPC flow as a proportion of total aortic (rho=0.31, P=0.04) and total pulmonary venous flow (rho=0.29, P=0.05). After adjustment for Fontan type and presence of a fenestration, absolute SPC flow was significantly associated with hospital duration ≥7 days (odds ratio [OR]=9.2, P=0.02) and chest tube duration ≥10 days (OR=22.7, P=0.009). Similar associations exist for SPC flow as a percentage of total aortic (OR=1.09, P=0.048 for hospitalization ≥7 days; OR=1.24, P=0.007 for chest tube duration ≥10 days) and total pulmonary venous flow (OR=1.07, P=0.048 for hospitalization ≥7 days; OR=1.18, P=0.006 for chest tube duration ≥10 days). CONCLUSIONS: Increasing SPC flow before Fontan, as measured by CMR imaging, is associated with increased duration of hospitalization and chest tube following Fontan completion.
BACKGROUND:Systemic-pulmonary collateral (SPC) flow occurs commonly in single ventricle patients after superior cavo-pulmonary connection, with unclear clinical significance. We sought to evaluate the association between SPC flow and acute post-Fontan clinical outcomes using a novel method of quantifying SPC flow by cardiac magnetic resonance (CMR) imaging. METHODS AND RESULTS: All patients who had SPC flow quantified by CMR imaging before Fontan were retrospectively reviewed to assess for acute clinical outcomes after Fontan completion. Forty-four subjects were included who had Fontan completion between May 2008 and September 2010. SPC flow prior to Fontan measured 1.5±0.9 L/min/m(2), accounting for 31±11% of total aortic flow and 44±15% of total pulmonary venous flow. There was a significant linear association between natural log-transformed duration of hospitalization and SPC flow as a proportion of total aortic (rho=0.31, P=0.04) and total pulmonary venous flow (rho=0.29, P=0.05). After adjustment for Fontan type and presence of a fenestration, absolute SPC flow was significantly associated with hospital duration ≥7 days (odds ratio [OR]=9.2, P=0.02) and chest tube duration ≥10 days (OR=22.7, P=0.009). Similar associations exist for SPC flow as a percentage of total aortic (OR=1.09, P=0.048 for hospitalization ≥7 days; OR=1.24, P=0.007 for chest tube duration ≥10 days) and total pulmonary venous flow (OR=1.07, P=0.048 for hospitalization ≥7 days; OR=1.18, P=0.006 for chest tube duration ≥10 days). CONCLUSIONS: Increasing SPC flow before Fontan, as measured by CMR imaging, is associated with increased duration of hospitalization and chest tube following Fontan completion.
Authors: J William Gaynor; Nancy D Bridges; Mitchell I Cohen; William T Mahle; William M Decampli; James M Steven; Susan C Nicolson; Thomas L Spray Journal: J Thorac Cardiovasc Surg Date: 2002-02 Impact factor: 5.209
Authors: S L Starnes; B W Duncan; J M Kneebone; G L Rosenthal; K Patterson; C H Fraga; K M Kilian; S K Mathur; F M Lupinetti Journal: J Thorac Cardiovasc Surg Date: 2001-09 Impact factor: 5.209
Authors: S L Starnes; B W Duncan; J M Kneebone; G L Rosenthal; T K Jones; R G Grifka; F Cecchin; D J Owens; C Fearneyhough; F M Lupinetti Journal: J Thorac Cardiovasc Surg Date: 2000-03 Impact factor: 5.209
Authors: Kevin K Whitehead; Matthew A Harris; Andrew C Glatz; Matthew J Gillespie; Michael V DiMaria; Neil E Harrison; Yoav Dori; Marc S Keller; Jonathan J Rome; Mark A Fogel Journal: Am J Cardiol Date: 2015-03-24 Impact factor: 2.778
Authors: Mark A Fogel; Christine Li; Felice Wilson; Tom Pawlowski; Susan C Nicolson; Lisa M Montenegro; Laura Diaz Berenstein; Thomas L Spray; J William Gaynor; Stephanie Fuller; Marc S Keller; Matthew A Harris; Kevin K Whitehead; Robert Clancy; Okan Elci; Jim Bethel; Arastoo Vossough; Daniel J Licht Journal: Heart Date: 2015-06-05 Impact factor: 5.994
Authors: Tacy E Downing; Kevin K Whitehead; Yoav Dori; Matthew J Gillespie; Matthew A Harris; Mark A Fogel; Jonathan J Rome; Andrew C Glatz Journal: Circ Cardiovasc Imaging Date: 2013-10-04 Impact factor: 7.792
Authors: Catherine M Avitabile; David J Goldberg; Mary B Leonard; Zhenglun Alan Wei; Elaine Tang; Stephen M Paridon; Ajit P Yoganathan; Mark A Fogel; Kevin K Whitehead Journal: Heart Date: 2017-10-07 Impact factor: 5.994
Authors: Jane W Newburger; Lynn A Sleeper; Peter C Frommelt; Gail D Pearson; William T Mahle; Shan Chen; Carolyn Dunbar-Masterson; Seema Mital; Ismee A Williams; Nancy S Ghanayem; Caren S Goldberg; Jeffrey P Jacobs; Catherine D Krawczeski; Alan B Lewis; Sara K Pasquali; Christian Pizarro; Peter J Gruber; Andrew M Atz; Svetlana Khaikin; J William Gaynor; Richard G Ohye Journal: Circulation Date: 2014-04-04 Impact factor: 29.690
Authors: Bassel Mohammad Nijres; Anas S Taqatqa; Lamya Mubayed; Gregory J Jutzy; Ra-Id Abdulla; Karim A Diab; Hoang H Nguyen; Brieann A Muller; Cyndi R Sosnowski; Joshua J Murphy; Joseph Vettukattil; Vishal R Kaley; Darcy N Marckini; Bennett P Samuel; Khaled Abdelhady; Sawsan Awad Journal: Pediatr Cardiol Date: 2018-08-13 Impact factor: 1.655